dc.contributor.author | Lofgren, Sarah M. | |
dc.contributor.author | Velamakanni, Sruti S. | |
dc.contributor.author | Hullsiek, Katherine Huppler | |
dc.contributor.author | Bangdiwala, Ananta S. | |
dc.contributor.author | Namudde, Alice | |
dc.contributor.author | Musubire, Abdu K. | |
dc.contributor.author | Mpoza, Edward | |
dc.contributor.author | Abassi, Mahsa | |
dc.contributor.author | . Pastick, Katelyn A | |
dc.contributor.author | Nuwagira, Edwin | |
dc.contributor.author | Evans, Emily E. | |
dc.contributor.author | Rajsasingham, Radha | |
dc.contributor.author | . Williams, Darlisha A | |
dc.contributor.author | Muzoora, Conrad | |
dc.contributor.author | Creswell, Fiona V. | |
dc.contributor.author | Rhein, Joshua | |
dc.contributor.author | Bond, David J. | |
dc.contributor.author | Nakasujja, Noeline | |
dc.contributor.author | Meya, David B. | |
dc.contributor.author | Boulware, David R. | |
dc.date.accessioned | 2022-05-19T13:44:49Z | |
dc.date.available | 2022-05-19T13:44:49Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Lofgren, S. M., Velamakanni, S. S., Hullsiek, K. H., Bangdiwala, A. S., Namudde, A., Musubire, A. K., ... & Boulware, D. R. (2021). The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis. Wellcome Open Research, 6(45), 45. | en_US |
dc.identifier.uri | http://ir.must.ac.ug/xmlui/handle/123456789/1987 | |
dc.description.abstract | Background: Depression is a risk factor for worse outcomes in persons living with HIV/AIDS and has a prevalence more than three times as high as in the general population. Despite this, there are few randomized studies of antidepressants in HIV-infected Africans.
Methods: We enrolled 460 HIV-infected Africans with cryptococcal meningitis into a randomized clinical trial of adjunctive sertraline vs placebo (2015-2017). We defined depression using depression using a Center for Epidemiologic Studies Depression Scale (CES-D) score of >15, and severe depression as >26 at one and three months after meningitis diagnosis and initiation of treatment.We evaluated the relationship between sertraline and depression, as well as associations with persistent depression, at three months.
Results: At one- and three-months post meningitis diagnosis, 62% (108/174) and 44% (74/169) of all subjects had depression (CES>15) respectively. At three months, sertraline-treated subjects had consistent risk for depression as placebo-treated subjects but were significantly less likely to have severe depression (CES>26) (OR 0.335; 95%CI, 0.130-0.865). Of those with depression at one month, sertraline-treated subjects were less likely than placebo-treated subjects to be depressed at three months (p=0.05). Sertraline was the only factor we found significant in predicting persistent depression at three months among those who had depression at one month.
Conclusions: Depression is highly prevalent in HIV-infected persons who have survived cryptococcal meningitis. We found that sertraline is associated with a modest reduction in depression in those with depression at baseline and a significant decrease in severe depression. | en_US |
dc.description.sponsorship | Wellcome Trust through a Clinical PhD Fellowship to FVC [210772] and through the Joint Global Health Trials scheme jointly funded by the UK Medical Research Council, UK Department for International Development and the Wellcome Trust [M007413/1]. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | Wellcome Open Research | en_US |
dc.subject | Depression | en_US |
dc.subject | HIV | en_US |
dc.subject | Sertraline | en_US |
dc.subject | Antidepressive Agents | en_US |
dc.subject | Depressive Disorder | en_US |
dc.subject | Treatment-Resistant | en_US |
dc.subject | Biomarkers | en_US |
dc.title | The effect of sertraline on depression and associations with persistent depression in survivors of HIV-related cryptococcal meningitis | en_US |
dc.type | Article | en_US |